News | November 23, 2023
Merck to acquire Caraway Therapeutics
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
The company has raised US$4.5 million in funding for its AI operating system
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
The companies plan to start a pivotal Phase 3 trial in the coming months
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Subscribe To Our Newsletter & Stay Updated
